Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis

Woehrl, Bianca, Brouwer, Matthijs C., Murr, Carmen, Heckenberg, Sebastiaan G.B., Baas, Frank, Pfister, Hans W., Zwinderman, Aeilko H., Morgan, Bryan Paul ORCID: https://orcid.org/0000-0003-4075-7676, Barnum, Scott R., Van der Ende, Arie, Koedel, Uwe and van de Beek, Diederik 2011. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. Journal of Clinical Investigation 121 (10) , pp. 3943-3953. 10.1172/JCI57522

Preview

PDF - Published Version Download (1MB) | Preview

Abstract

Pneumococcal meningitis is the most common and severe form of bacterial meningitis. Fatality rates are substantial, and long-term sequelae develop in about half of survivors. Disease outcome has been related to the severity of the proinflammatory response in the subarachnoid space. The complement system, which mediates key inflammatory processes, has been implicated as a modulator of pneumococcal meningitis disease severity in animal studies. Additionally, SNPs in genes encoding complement pathway proteins have been linked to susceptibility to pneumococcal infection, although no associations with disease severity or outcome have been established. Here, we have performed a robust prospective nationwide genetic association study in patients with bacterial meningitis and found that a common nonsynonymous complement component 5 (C5) SNP (rs17611) is associated with unfavorable disease outcome. C5 fragment levels in cerebrospinal fluid (CSF) of patients with bacterial meningitis correlated with several clinical indicators of poor prognosis. Consistent with these human data, C5a receptor–deficient mice with pneumococcal meningitis had lower CSF wbc counts and decreased brain damage compared with WT mice. Adjuvant treatment with C5-specific monoclonal antibodies prevented death in all mice with pneumococcal meningitis. Thus, our results suggest C5-specific monoclonal antibodies could be a promising new antiinflammatory adjuvant therapy for pneumococcal meningitis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Additional Information:	Pdf uploaded in accordance with publisher's policy at http://www.sherpa.ac.uk/romeo/issn/0021-9738/ (accessed 24/02/2014)
Publisher:	American Society for Clinical Investigation
ISSN:	0021-9738
Date of First Compliant Deposit:	30 March 2016
Last Modified:	24 May 2023 00:12
URI:	https://orca.cardiff.ac.uk/id/eprint/28652

Citation Data

Cited 82 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item